Granules shares gain over 5% on U.S. FDA nod for ADHD generic capsules
Granules India receives FDA approval for generic ADHD drug, expanding portfolio and reinforcing presence in treatment space.
Adderall shortage sparks scramble for ADHD medication alternatives
Adderall shortages have prompted doctors to switch kids with attention-deficit/hyperactivity disorder to other forms of ...
Granules India gets USFDA’s nod for ADHD generic
Granules India's subsidiary, GPI, receives USFDA approval for Lisdexamfetamine Dimesylate Capsules, expanding ADHD treatment ...
Granules India Limited receives final approval from USFDA for its new drug
Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and ...
HealthDay on MSN3d
Adderall Shortage Sparks Scramble for ADHD Alternatives
Adderall shortages have prompted doctors to switch kids with attention-deficit/hyperactivity disorder (ADHD) to other ...
Nasdaq3d
FDA Approves Qelbree Label For ADHD And Lactation
Qelbree is now the first ADHD treatment to meet the FDA's post-marketing requirement for lactation studies, following the 2019 guidance on Clinical Lactation Studies. Supernus believes that this ...
Monthly Prescribing Reference4d
Labeling for ADHD Med Qelbree Updated With Lactation, Pharmacodynamic Data
The updated labeling for Qelbree provides additional information on the pharmacodynamic profile of the drug. Findings show ...
6 Things To Know About Stimulant Medications For ADHD
Stimulant medications are considered the first-line treatment for ADHD for some very good reasons. Here are 6 things to know ...
FDA bans Red No. 3, but experts warn of ongoing gaps in food safety regulations
The Food and Drug Administration announced last week that it will revoke authorization for FD&C Red No. 3 in food and ...
STAT2d
Kids with ADHD and the Adderall shortage
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good ...
Study: People with ADHD have shorter life expectancy, higher risk of mental health issues
Having ADHD is associated with a shorter life expectancy and a greater risk of mental health issues, according to a new study ...
Investing4d
FDA approves Qelbree label update for ADHD treatment
has announced the FDA approval of a label update for its ADHD treatment, Qelbree. The company, currently valued at $2.1 billion and trading near its 52-week high, has received FDA approval for ...